Last Updated: September 24, 2026

Endo Operations Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for ENDO OPERATIONS

ENDO OPERATIONS has twenty approved drugs.

There are seven US patents protecting ENDO OPERATIONS drugs.

Summary for Endo Operations

US Patents:	7
Tradenames:	21
Ingredients:	17
NDAs:	20
Patent Litigation for Endo Operations:	See patent lawsuits for Endo Operations

Drugs and US Patents for Endo Operations

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Endo Operations	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021610-003	Jun 22, 2006		DISCN	Yes	No	8,808,737	⤷ Start Trial				⤷ Start Trial
Endo Operations	SUPPRELIN LA	histrelin acetate	IMPLANT;SUBCUTANEOUS	022058-001	May 3, 2007		RX	Yes	Yes	8,062,652	⤷ Start Trial				⤷ Start Trial
Endo Operations	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021610-005	Feb 29, 2008		DISCN	Yes	No	8,871,779	⤷ Start Trial		Y		⤷ Start Trial
Endo Operations	LEVATOL	penbutolol sulfate	TABLET;ORAL	018976-001	Dec 30, 1987		DISCN	Yes	No		⤷ Start Trial				⤷ Start Trial
Endo Operations	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021610-002	Jun 22, 2006		DISCN	Yes	No	8,871,779	⤷ Start Trial		Y		⤷ Start Trial
Endo Operations	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021610-006	Feb 29, 2008		DISCN	Yes	No	8,808,737	⤷ Start Trial				⤷ Start Trial
Endo Operations	FORTESTA	testosterone	GEL, METERED;TRANSDERMAL	021463-001	Dec 29, 2010		DISCN	Yes	No		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Endo Operations

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Endo Operations	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021610-003	Jun 22, 2006	5,128,143	⤷ Start Trial
Endo Operations	MEGACE ES	megestrol acetate	SUSPENSION;ORAL	021778-001	Jul 5, 2005	9,101,540	⤷ Start Trial
Endo Operations	MEGACE ES	megestrol acetate	SUSPENSION;ORAL	021778-001	Jul 5, 2005	9,040,088	⤷ Start Trial
Endo Operations	FROVA	frovatriptan succinate	TABLET;ORAL	021006-001	Nov 8, 2001	5,637,611	⤷ Start Trial
Endo Operations	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021610-004	Jun 22, 2006	5,128,143	⤷ Start Trial
Endo Operations	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021610-002	Jun 22, 2006	5,958,456	⤷ Start Trial
Endo Operations	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021610-006	Feb 29, 2008	5,958,456	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for ENDO OPERATIONS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Gel	1%	➤ Subscribe	2008-08-21
➤ Subscribe	Extended-release Tablets	5 mg, 10 mg, 20 mg and 40 mg	➤ Subscribe	2007-11-23
➤ Subscribe	Extended-release Tablets	30 mg	➤ Subscribe	2008-06-12
➤ Subscribe	Gel	10 mg/actuation	➤ Subscribe	2012-08-14
➤ Subscribe	Injection	250 mg/mL	➤ Subscribe	2014-06-11
➤ Subscribe	Extended-release Tablets	7.5 mg and 15 mg	➤ Subscribe	2008-05-29
➤ Subscribe	Tablets	2.5 mg	➤ Subscribe	2011-03-09
➤ Subscribe	Nasal Spray	500 mcg/spray	➤ Subscribe	2017-04-28

International Patents for Endo Operations Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Australia	2003219086	⤷ Start Trial
South Korea	20050109561	⤷ Start Trial
China	1761469	⤷ Start Trial
Slovenia	1457208	⤷ Start Trial
European Patent Office	1994034	⤷ Start Trial
Iceland	8069	⤷ Start Trial
Norway	335179	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Endo Operations Drugs

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0591280	C300103	Netherlands	⤷ Start Trial	PRODUCT NAME: FROVATRIPTAN EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 27211RVG 27212 2002190419; FIRST REGISTRATION: NL 24548 20001212
0591280	01C0019	France	⤷ Start Trial	PRODUCT NAME: FROVATRIPTAN SUCCINATE MONOHYDRATE; NAT. REGISTRATION NO/DATE: NL 24548 20001212; FIRST REGISTRATION: FR - NL 24548 20001212
0591280	SPC/GB03/014	United Kingdom	⤷ Start Trial	PRODUCT NAME: 3 METHYLAMINO-6-CARBOXAMIDO-1, 2, 3, 4-TETRAHYDROCARBAZOLE ("FROVATRIPTAN") INCLUDING A SALT, SOLVATE OR HYDRATE THEREOF; REGISTERED: FR NL 24548 20001212; UK PL 16239/0017 20021007; UK PL 16239/0018 20021007
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.